Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD.

Maltais F, Hamilton A, Voß F, Maleki-Yazdi MR.

Adv Ther. 2019 Apr;36(4):962-968. doi: 10.1007/s12325-019-00911-y. Epub 2019 Mar 6.


New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology.

D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 7;13:2805-2819. doi: 10.2147/COPD.S113306. eCollection 2018. Review.


Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol.

Koch A, Watz H, Maleki-Yazdi MR, Bothner U, Tetzlaff K, Voß F, McGarvey L.

NPJ Prim Care Respir Med. 2017 Oct 23;27(1):60. doi: 10.1038/s41533-017-0059-1.


Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.

Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I.

Int J Chron Obstruct Pulmon Dis. 2016 Jun 24;11:1413-24. doi: 10.2147/COPD.S101612. eCollection 2016.


Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.

Aalbers R, Maleki-Yazdi MR, Hamilton A, Waitere-Wijker S, Zhao Y, Amatto VC, Schmidt O, Bjermer L.

Adv Ther. 2015 Sep;32(9):809-22. doi: 10.1007/s12325-015-0239-8. Epub 2015 Sep 24.


A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.

Maleki-Yazdi MR, Beck E, Hamilton AL, Korducki L, Koker P, Fogarty C.

Respir Med. 2015 May;109(5):596-605. doi: 10.1016/j.rmed.2015.02.012. Epub 2015 Mar 3.


Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.

Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.

Respir Med. 2013 Oct;107(10):1538-46. doi: 10.1016/j.rmed.2013.06.001. Epub 2013 Jul 2.


The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada.

Maleki-Yazdi MR, Kelly SM, Lam SY, Marin M, Barbeau M, Walker V.

Can Respir J. 2012 Sep-Oct;19(5):319-24.


Early detection and impaired quality of life in COPD GOLD stage 0: a pilot study.

Maleki-Yazdi MR, Lewczuk CK, Haddon JM, Choudry N, Ryan N.

COPD. 2007 Dec;4(4):313-20.


Effects of oxygen withdrawal on catecholamine release in patients on home oxygen therapy.

Balter MS, Chapman KR, Maleki-Yazdi MR, Leenen FH, Rebuck AS.

Clin Sci (Lond). 1990 Aug;79(2):155-9.


Supplemental Content

Loading ...
Support Center